TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00440401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fibrinogen (human) + thrombin (human)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard haemostatic treatment in cardiovascular surgery
Description: Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)
Study: NCT01938625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.
Study: NCT03605901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dosing of methadone
Description: Subject will receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliquots of methadone titrated to apnea
Description: Subjects will receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 5-10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals.
Study: NCT03591822

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A : Systemic evaluation of the pain and mediation with the PARO therapeutic robot
Description: Each session with the PARO robot will encompasses the same four following steps (a) Meeting Paro (b) Proposing contact (c) Individually using Paro during the care (d) End of the exposure.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A : Systemic evaluation of the pain and mediation with the PARO therapeutic robot
Description: Each session with the PARO robot will encompasses the same four following steps (a) Meeting Paro (b) Proposing contact (c) Individually using Paro during the care (d) End of the exposure.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: B : Systemic evaluation of the pain
Description: A systematic evaluation of the pain

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: B : Systemic evaluation of the pain
Description: A systematic evaluation of the pain
Study: NCT02509546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8-Chloroadenosine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8-Chloroadenosine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8-Chloroadenosine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8-Chloroadenosine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8-Chloroadenosine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8-Chloroadenosine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT04321863

Intervention type: OTHER
Intervention: Faecal calprotectin (FC)
Description: FC is a surrogate marker of neutrophil influx into the gut lumen. It accurately predicts mucosal healing (MH) at colonoscopy, and thus is already widely used in clinical practice in disease monitoring in CD patients (standard of care).

Intervention type: OTHER
Intervention: quantitative Faecal Immunochemical Testing (qFIT)
Description: Stool test for haemoglobin. It has been shown to predict mucosal healing in Crohn's disease and ulcerative colitis. This study will compare the ability of qFIT and FC to predict flare in CD (qFIT is a cheaper, more stable test with a quicker turn-around time than FC, and is also less labour intensive for the lab).

Intervention type: OTHER
Intervention: Serum and faecal zinc
Description: Blood sample for serum zinc will be taken at same time as routine (standard of care) monitoring bloods which include CRP - no additional venipuncture will be required. A single stool sample will be sufficient to measure FC (as outlines above) and faecal zinc. This study will compare the ability of serum/faecal zinc and CRP at predicting relapse in patients with quiescent (inactive) luminal (affecting the small and/or large bowel) CD.
Study: NCT03485612

Intervention type: DIAGNOSTIC_TEST
Intervention: Change of Optic Nerve Sheath Diameter
Description: In patients, the optic nerve sheath width (ONSD) examination will be performed twice: for the first time immediately after general anesthesia and again after surgery after placing the patient in a position on the back.
Study: NCT01349738

Intervention type: DRUG
Intervention: Antibiotic
Description: Antibiotic (drug) sensitive to most recent culture for these subjects testing ASB positive and also experience Signs and symptoms of a UTI
Study: NCT00364910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants meet with a therapist for three to five sessions brief exposure-based CBT.
Study: NCT02287961

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard proctologic examination
Description: (with digital rectal examination and 2 anal swabs) at initial inclusion visit, M12 and M24 follow-up visits and if applicable M6 and M18 control visits
Study: NCT02675491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6051b
Description: Drug: DS-6051b 400 mg or 800 mg daily
Study: NCT00471107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC brain polarization
Description: 0.08 mA/cm2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DC brain polarization
Description: 0.08 mA/cm2
Study: NCT01123564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Argon laser treatment
Description: Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.
Study: NCT00787488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Every 3 weeks
Study: NCT00793611

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral therapy standard of care
Description: controls will receive usual interventions for overactive bladder: voiding diary, bladder drills, pelvic floor exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy standard of care
Description: controls will receive usual interventions for overactive bladder: voiding diary, bladder drills, pelvic floor exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypnotherapy
Description: Patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatment of overactive bladder
Study: NCT04011709

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: VR647 Inhalation System + VR647 Smart Card 3 Secs
Description: 3 attempts of 19 inhalations, 3 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: VR647 Inhalation System + VR647 Smart Card 3 Secs
Description: 3 attempts of 19 inhalations, 3 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
Study: NCT02287961

Intervention type: PROCEDURE
Group type: OTHER
Intervention: High resolution anoscopy
Description: at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy(ies) during High Resolution Anoscopy
Description: only if lesion suggestive of AIN detected during High Resolution Anoscopy
Study: NCT04011709

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: VR647 Inhalation System + VR647 Smart Card 2 Secs
Description: 3 attempts of 28 inhalations, 2 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: VR647 Inhalation System + VR647 Smart Card 4 Secs
Description: 3 attempts of 14 inhalations, 4 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
Study: NCT04516200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation and traditional physical therapy program
Description: Transcranial stimulation will be applied only for the study group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: designed physical therapy program
Description: sensory training and balance training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: designed physical therapy program
Description: sensory training and balance training
Study: NCT04928586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMARDs
Description: CTD-ILD patients treated with DMARDs according to the condition of the disease
Study: NCT00364910

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational session and treatment as usual
Description: Participants assigned to the educational session attend one meeting with a researcher to discuss the results from their evaluation. They could also be referred to a mental health clinic of their choice to help relieve their symptoms.
Study: NCT03358628

Intervention type: OTHER
Intervention: Molecular Profiling & In Vivo drug testing in PDX
Description: Molecular profiling of host tumour sample and PDX will be performed and analyzed by an expert panel. In vitro drug testing using organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo PDX drug testing results will be made, if available.
Study: NCT03077048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketosteril®
Description: Patients will be randomised to receive isonitrogenous and isocaloric LPD providing 0.6 g protein/kg BW/day and an energy intake of 30-35 kcal/kg BW/day with (test group) or without (control group) intake of Ketosteril® (1 tablet/5 kg BW/day). The control group will get additional food protein to balance the nitrogen content of Ketosteril® The mainly vegetarian diet will be maintained for 10 days.
Study: NCT02031900

Intervention type: DEVICE
Intervention: NvisionVLE Imaging System: NvisionVLE Imaging Console, NvisionVLE Optical Probe and Inflation Accessory Kit
Description: The NvisionVLE Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization.
Study: NCT03291002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV8102
Description: CV8102 alone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV8102
Description: CV8102 alone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV8102 + anti-PD-1 therapy
Description: CV8102 in combination with standard of care anti-PD-1 therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV8102 + anti-PD-1 therapy
Description: CV8102 in combination with standard of care anti-PD-1 therapy
Study: NCT03063255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obturator block
Description: Subjects allocated to the obturator block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to post-anaesthesia care unit (PACU) or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular block
Description: Subjects allocated to the neuromuscular block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to PACU or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
Study: NCT01025336

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: Group 1.1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1 Group 1.2- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: Group 1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPNC was administered in the deltoid muscle at year 1
Study: NCT02975648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational model + follow up
Description: Orientation from health professionals at discharge, educational program with explanation of booklets and telephone follow-up (three calls)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Hospital health professionals offered orientation on care after discharge
Study: NCT04074993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
Study: NCT02296346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SoluMedrol
Description: Infusion of drug subcutaneously, once a month.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis
Description: This intervention is the placement of up to two IV's to extract your blood as a set volume, separate out the white cells and return the red cells to your body. Then the white cells are treated with a drug called UVADEX (methoxsalen), excited by a UV light and returned to your body. Once IV is to withdraw your blood and the other is to return your blood to your body.
Study: NCT04236453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
Description: Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally on Day 1 of treatment periods with Treatment A.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
Description: Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally on Day 1 of treatment periods with Treatment A.
Study: NCT02287961

Intervention type: PROCEDURE
Group type: OTHER
Intervention: High Resolution Anoscopy biannually
Description: Only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
Study: NCT03031821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin Duration: 18 months 850 mg PO OD x 30 days then 850 mg PO BID for duration
Study: NCT04236453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Participants will receive a single dose of Darunavir orally on Day 1 of treatment periods with Treatment B.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Participants will receive a single dose of Darunavir orally on Day 1 of treatment periods with Treatment B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Alafenamide
Description: Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/Tenofovir Alafenamide
Description: Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally on Day 1.
Study: NCT03031821

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet Duration 18 months~1 tablet (850 mg) PO OD x 30 days then 1 tablet PO BID for duration
Study: NCT03685305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with hunger reduction strategy
Description: Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. Counseling will include specific instructions on a dietary manipulation which may reduce hunger, in order to facilitate dietary adherence.This will include tracking of the strategy. They will also be provided a pedometer and instructed to attain 10,000 steps per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet without hunger reduction strategy
Description: Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
Study: NCT04236453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Participant will receive a single dose of Cobicistat tablet orally on Day 1.
Study: NCT02087423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 (durvalumab) by intravenous infusion every two weeks. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier. Patients who achieve CR, PR or SD through the end of the initial 12-month treatment period can restart treatment with MEDI4736 (durvalumab) when they eventually do progress. This retreatment period can continue for as long as the investigator considers to patient to be receiving clinical benefit.
Study: NCT03532282

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ONLINE ONLY
Description: Access to an online cognitive behavioral therapy for insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPPED CARE
Description: A two step treatment that starts with either an online or therapist led cognitive behavioral therapy for insomnia, depending on a decision algorithm (checklist). Those with insufficient progress to the online treatment after 8 weeks are switched to a therapist-led treatment